Lurbinectedin is a chemotherapy drug that is currently approved for the treatment of metastatic small cell lung cancer (SCLC) in the United States and Europe [3]. It is not approved for the treatment of other types of cancer at this time [1].

Lurbinectedin is a synthetic compound that was derived from a sea squirt, and it works by inhibiting the transcription of DNA in cancer cells [2]. It has shown promising results in clinical trials for other types of cancer, including ovarian cancer and triple-negative breast cancer, but it has not yet been approved for these indications [2].

In summary, lurbinectedin is currently only approved for the treatment of metastatic SCLC and is not approved for the treatment of other types of cancer at this time. However, it has shown potential in clinical trials for other types of cancer, and further research is ongoing [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532454/
[3] https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin